CN100393318C - 一种积雪苷外用无菌粉剂及制备方法 - Google Patents
一种积雪苷外用无菌粉剂及制备方法 Download PDFInfo
- Publication number
- CN100393318C CN100393318C CNB2006100501871A CN200610050187A CN100393318C CN 100393318 C CN100393318 C CN 100393318C CN B2006100501871 A CNB2006100501871 A CN B2006100501871A CN 200610050187 A CN200610050187 A CN 200610050187A CN 100393318 C CN100393318 C CN 100393318C
- Authority
- CN
- China
- Prior art keywords
- asiaticoside
- preparation
- powder
- sterile powder
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 title claims abstract description 48
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 title claims abstract description 47
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 title claims abstract description 47
- 229940022757 asiaticoside Drugs 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000000843 powder Substances 0.000 title claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000001914 filtration Methods 0.000 claims abstract description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000006184 cosolvent Substances 0.000 claims abstract description 12
- 238000004108 freeze drying Methods 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 230000001954 sterilising effect Effects 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 241000894006 Bacteria Species 0.000 claims abstract 2
- 229930182470 glycoside Natural products 0.000 claims description 15
- 150000002338 glycosides Chemical class 0.000 claims description 15
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- 238000012856 packing Methods 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000005262 decarbonization Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 15
- 239000000243 solution Substances 0.000 abstract description 12
- 239000008215 water for injection Substances 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 14
- 241000699660 Mus musculus Species 0.000 description 10
- 238000011580 nude mouse model Methods 0.000 description 10
- 231100000241 scar Toxicity 0.000 description 8
- 210000000589 cicatrix Anatomy 0.000 description 7
- 229960004011 methenamine Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000009287 sand filtration Methods 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 238000007639 printing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000005374 membrane filtration Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000167550 Centella Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000835 hypertrophic cicatrix Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 201000008962 Nezelof syndrome Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 201000001322 T cell deficiency Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- -1 routine urinalysis Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
助溶剂类别 | 总苷(折纯)加入量 | 助溶剂加入量 | 溶解体积 | 加热溶解情况 | 冷却析出情况 |
十二烷基硫酸钠 | 2.5g | 1.0g | 40ml | 溶解 | 未析出,澄清 |
糖精钠 | 2.5g | 1.0g | 40ml | 溶解 | 析出 |
葡甲胺 | 2.5g | 1.0g | 40ml | 溶解 | 析出 |
乌洛托品 | 2.5g | 1.0g | 40ml | 溶解 | 稍有析出 |
柠檬酸钠 | 2.5g | 1.0g | 40ml | 溶解 | 析出 |
苯甲酸钠 | 2.5g | 1.0g | 40ml | 溶解 | 析出 |
硫脲 | 2.5g | 1.0g | 40ml | 溶解 | 析出 |
烟酰胺 | 2.5g | 1.0g | 40ml | 溶解 | 析出 |
聚乙二醇4000 | 2.5g | 1.0g | 40ml | 溶解 | 析出 |
氨基胍 | 2.5g | 1.0g | 40ml | 溶解 | 析出 |
批号 | 050601 | 050701 | 050702 | 050703 |
批量(ml) | 4000 | 4000 | 4000 | 4000 |
灌装量(ml) | 4 | 4 | 4 | 4 |
理论量(瓶) | 1000 | 1000 | 1000 | 1000 |
实际量(瓶) | 982 | 952 | 937 | 961 |
成品率(%) | 98.2 | 95.2 | 93.7 | 96.1 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100501871A CN100393318C (zh) | 2006-04-04 | 2006-04-04 | 一种积雪苷外用无菌粉剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100501871A CN100393318C (zh) | 2006-04-04 | 2006-04-04 | 一种积雪苷外用无菌粉剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1830450A CN1830450A (zh) | 2006-09-13 |
CN100393318C true CN100393318C (zh) | 2008-06-11 |
Family
ID=36993051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100501871A Expired - Fee Related CN100393318C (zh) | 2006-04-04 | 2006-04-04 | 一种积雪苷外用无菌粉剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100393318C (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1733265A (zh) * | 2005-07-29 | 2006-02-15 | 王衡新 | 用于伤科和皮肤科的中药注射剂及其制备方法 |
-
2006
- 2006-04-04 CN CNB2006100501871A patent/CN100393318C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1733265A (zh) * | 2005-07-29 | 2006-02-15 | 王衡新 | 用于伤科和皮肤科的中药注射剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1830450A (zh) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104163847B (zh) | 蝇蛆活性蛋白肽的制备方法与所制备的蝇蛆活性蛋白肽及其用途 | |
CN112316017A (zh) | 一种妇科抑菌凝胶及其制备方法 | |
CN109865033A (zh) | 一种外敷药膏及其在修复糖尿病足创伤中的应用 | |
CN106668331A (zh) | 一种具有消炎抑菌及促进创面愈合的组合物及制配方法 | |
CN100393318C (zh) | 一种积雪苷外用无菌粉剂及制备方法 | |
CN112675354B (zh) | 一种多功能白及医用材料及其制备方法与应用 | |
CN115025137A (zh) | 一种外用促进创面愈合的中药提取物及其提取方法和应用 | |
CN116496971A (zh) | 艾叶来源外泌体样纳米囊泡及其应用和药物 | |
CN113952498B (zh) | 一种中药多组分液体愈创敷料及制备方法 | |
RU2342955C1 (ru) | Способ получения антисептической пленки | |
CN101897693B (zh) | 儿茶素类化合物或含其的植物提取物的应用及药物组合物 | |
CN102139071B (zh) | 一种治疗妇科炎症的中药软胶囊剂及其制备方法 | |
CN112169008A (zh) | 一种基于人源胶原蛋白的医用敷料的制备方法 | |
CN111265550A (zh) | 一种修复损伤组织的干细胞因子脂质体及其制备方法 | |
CN116103219B (zh) | 一种雪莲干细胞粉的制备方法及其制得的抑菌剂 | |
CN117815443B (zh) | 一种保护透析血管通路的外用敷料及其制备方法 | |
CN102462785A (zh) | 一种治疗“艾滋病病毒”的药物组合物及其制备方法 | |
CN107397858B (zh) | 一种治疗皮肤病的外用药及制备方法 | |
CN116077567B (zh) | 一种金丝桃促创面愈合药物组合物及其制备方法与应用 | |
CN114149515A (zh) | 天然可降解医用敷料葡配甘露聚糖的制备方法及其应用 | |
CN110711225A (zh) | 一种治疗口腔溃疡的药物组合物及其制备方法 | |
CN103655671A (zh) | 鹿瓜多肽药物组合物及其制备方法 | |
CN102114078B (zh) | 促进骨折愈合的中药提取物及其制备方法和应用 | |
CN112807270A (zh) | 一种间充质干细胞分泌因子与内容物和蒲公英干细胞提取物组合物及其制备方法 | |
CN117919299A (zh) | 一种鲜黄芪来源纳米颗粒的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Zhejiang Conba Health Products Co., Ltd. Assignor: Hangzhou Yinnuobang Medicine Science & Technology Co., Ltd. Contract fulfillment period: 2008.9.1 to 2013.12.31 Contract record no.: 2009330000263 Denomination of invention: Asiaticoside external use sterile powder and its preparation method Granted publication date: 20080611 License type: Exclusive license Record date: 20090213 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.9.1 TO 2013.12.31; CHANGE OF CONTRACT Name of requester: ZHEJIANG CONBA HEALTH PRODUCT CO,.LTD. Effective date: 20090213 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Zhejiang Conba Health Products Co., Ltd. Assignor: Hangzhou Yinnuobang Medicine Science & Technology Co., Ltd. Contract record no.: 2009330000263 Date of cancellation: 20150108 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060913 Assignee: Zhejiang Kangnuobang Health Products Co., Ltd. Assignor: Hangzhou Yinnuobang Medicine Science & Technology Co., Ltd. Contract record no.: 2015330000013 Denomination of invention: Asiaticoside external use sterile powder and its preparation method Granted publication date: 20080611 License type: Exclusive License Record date: 20150123 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080611 Termination date: 20190404 |